US President Donald Trump on August 11 announced a $ 1.5 billion contract with American biotechnology company Moderna to produce 100 million doses of Covid-19 vaccine.
“I am pleased to announce that we have reached an agreement to manufacture and supply 100 million doses of Moderna’s coronavirus vaccine,” Trump said at a press conference in the White House. “The federal government will get these vaccines, we are buying them.
“We will quickly make 100 million doses as soon as the vaccine is approved and then we can go up to 500 million doses. Therefore, we will have 600 million doses of vaccine, “Trump said.
President of the United States , Donald Trump said in a press conference on Tuesday 11/8 Covid-19 at the White House.
The vaccine, called mRNA-1273, is being studied by Moderna in partnership with the National Institute for Allergy and Infectious Diseases (NIAID) and is undergoing phase 3 clinical trials.
NIAID director Anthony Fauci said researchers can only determine the effectiveness of the vaccine as early as the end of the year. But Mr Trump said he hopes to have a vaccine before the November 3 presidential election.
The latest deal brings the total amount of money the US government signed with Moderna to $ 2.48 billion .
The Moderna Company was founded less than 10 years ago and has not developed any vaccines before. However, the company’s preliminary results for the Covid-19 vaccine being tested have shown promising results.
The Trump administration has allocated at least $ 10.9 billion in total to the development and production of the coronavirus vaccine.
The US Department of Health and Human Services (HHS) previously said it would pay Pfizer and biotech company BioNTech $ 1.95 billion to produce and distribute 100 million doses of Covid-19 vaccine. The deal will also allow the US to purchase an additional 500 million doses if needed.
HHS also announced that it will pay Johnson & Johnson more than $ 1 billion for 100 million doses and have the right to buy 200 million more doses.
The government also reached a $ 2.1 billion agreement with Sanofi and GlaxoSmithKline to develop and provide 100 million doses of vaccine with the option of purchasing an additional 500 million doses.